Leo Pharma announces another round of job cuts

11 October 2024

Danish dermatology specialist Leo Pharma has revealed plans to cut more jobs, marking the company’s fourth workforce reduction since 2022.

The latest layoffs follow previous rounds of cuts, including 300 positions in 2023 and another 100 this year, making job losses since 2019 of just under 2,000.

The move is part of a broad overhaul under chief executive Christophe Bourdon, who was appointed in 2022, bringing with him a focus on improving efficiency and boosting innovation through new R&D partnerships.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK